$TRVI News

Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform

Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28

Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25

Cantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30

Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcript

Trevi Therapeutics Q2 EPS $(0.11), Inline

BMO Capital Initiates Coverage On Trevi Therapeutics with Outperform Rating, Announces Price Target of $36

B. Riley Securities Maintains Buy on Trevi Therapeutics, Raises Price Target to $31

HC Wainwright & Co. Maintains Buy on Trevi Therapeutics, Raises Price Target to $24

Trevi Therapeutics Announces Upcoming June and July Event Schedule

Needham Reiterates Buy on Trevi Therapeutics, Maintains $23 Price Target

Trevi Therapeutics, Inc. (TRVI) Analyst/Investor Day - Slideshow

Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript

Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030

Trevi Therapeutics, Inc. Q1 2026 Earnings Call Summary

Why Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030

HC Wainwright & Co. Reiterates Buy on Trevi Therapeutics, Maintains $21 Price Target

Needham Maintains Buy on Trevi Therapeutics, Lowers Price Target to $23

Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript

Trevi Therapeutics Q1 Earnings Call Highlights